Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal

Thrombosis and Haemostasis

Volumn 112, Issue 3, 2014, Pages 621-623

  Dentali, Francesco ^a   Imberti, Davide ^b   Permunian, Eleonora Tamburini ^a   Croci, Ezio ^b   Ageno, Walter ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b Piacenza Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 7; PROTHROMBIN COMPLEX; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; PROTHROMBIN COMPLEX CONCENTRATES; VITAMIN K GROUP;

ADULT; AGED; ARTERIAL THROMBOEMBOLISM; ATRIAL FIBRILLATION; BLEEDING; COHORT ANALYSIS; CONGESTIVE CARDIOMYOPATHY; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MECHANICAL HEART VALVE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SYNAPTIC EFFICACY; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPLICATION; HEMORRHAGE; MIDDLE AGED; THROMBOEMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; COHORT STUDIES; HEMORRHAGE; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 84933053114     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-10-0851     Document Type: Letter

References (12)

1. Ageno W, Gallus AS, Wittkowsky A, et al; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest 2012; 141 (2 Supplement): e44S-488S.
2. Palareti G, Leali N, Coccheri S, et aò Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428.
3. Ageno W, Garcia D, Aguilar MI, et al. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. Am J Hematol 2009; 84: 584-588.
4. Libby EN, Garcia DA. A survey of oral vitamin K use by anticoagulation clinics. Arch Intern Med 2002; 162: 1893–1896.
5. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 4: 1853–1863.
6. Samama CM. Prothrombin complex concentrates: a brief review. Eur J Anaesthesiol 2008; 25: 784–789.
7. Dentali F, Marchesi C, Pierfranceschi MG, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 2011; 106: 429-438.
8. Baggs JH, Patanwala AE, Williams EM, et al. Dosing of 3-factor prothrombin complex concentrate for international normalized ratio reversal. Ann Pharmacother 2012; 46: 51-56.
9. Holland L, Warkentin TE, Refaai M, et al. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009; 49: 1171-1177.
10. Imberti D, Magnacavallo A, Dentali F, et al. Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding. J Thromb Thrombolysis 2013; 36: 102-108.
11. Imberti D, Barillari G, Biasioli C, et al. Prothrombin complex concentrates for urgent anticoagulation reversal in patients with intracranial haemorrhage. Pathophysiol Haemost Thromb 2008; 36: 259-265.
12. Menzin J, Hoesche J, Friedman M, et al. Failure to correct International Normalized Ratio and mortality among patients with warfarin-related major bleeding: an analysis of electronic health records. J Thromb Haemost 2012; 10: 596-605.